Search

A study funded by the developer of an extended-release liquid formulation of methylphenidate has found that the formulation effectively reduced symptoms of attention-deficit hyperactivity disorder (ADHD) in children ages 6 [...]

This is a summary of the most important information about OROS methylphenidate (Concerta). For details, talk to your healthcare professional. What is Concerta? Concerta is in a class of medications [...]

This is a summary of some of the most important information about methylphenidate. For more details, talk to your healthcare professional. What is methylphenidate? Methylphenidate is in a class of [...]

An editorial by Sam Goldstein, Ph.D., Editor-in-Chief of the Journal of Attention Disorders, reviews data from a controversial study conducted by L-Zein et al. (2005) that suggested that methylphenidate (MPH) [...]

Four doses of psychostimulant medication, combining extended-release methylphenidate at breakfast with immediate-release methylphenidate in the afternoon, were administered in a placebo-controlled design. While long-acting formulations of psychostimulant medication are the [...]

A study involving healthy college students has found that the stimulant medication methylphenidate (MPH) shows variable effects as a function of task demands and baseline memory capacity. Authors of the [...], * Nineteen healthy young adults participated in a number of tests after administration of 20 mg of methylphenidate (MPH) or placebo on two different occasions, to analyze possible differences in reward and punishment learning based on the presence of high or low working memory capacity. * Use of MPH improved reward vs. punishment learning in high working memory individuals, while low working memory students saw the opposite effect. * The results illustrate potential differences in medication response both among individuals and within the same individual, and warrant careful analysis of use of MPH in the healthy population.

Methylphenidate significantly increased cigarette smoking in a small within-subjects study of young adults (mean age, 24 years) with attention-deficit/hyperactivity disorder (ADHD). University of Kentucky researchers conducted the study to measure [...]

School children with attention-deficit/hyperactivity disorder (ADHD) treated with Osmotic-Release Oral System (OROS) methylphenidate (MPH) showed significant improvements in ADHD core symptoms, classroom behavior, productivity, and attention to tasks, compared with [...]

precis * Immediate-release methylphenidate (MPH-IR) was highly effective in reducing ADHD symptoms in children with both ADHD and chronic multiple tic disorder and comorbid anxiety disorder (+ANX), according to an [...]

Within 4 weeks of switching from extended-release methylphenidate (ER MPH) to a carefully titrated optimal dose of the MPH transdermal system (MTS), caregivers of children with attention-deficit/hyperactivity disorder (ADHD) reported [...], * Abruptly switching from extended-release methylphenidate [ER MPH] to the MPH transdermal system [MTS] improved ADHD behavior and quality of life in ADHD children, according to a 4-week, open-label study. * The patients enrolled were struggling with efficacy, tolerability, or compliance with the ER MPH. * The majority of caregivers reported high satisfaction with the MTS, improved behavior, and less worry about missed doses.

precis * Augmenting atomoxetine treatment with extended-release OROS methylphenidate in children with ADHD appears to be safe; however efficacy was no greater with combination treatment than with atomoxetine + placebo [...]

The U.S. Food and Drug Administration (FDA) is warning that methylphenidate products, one type of stimulant drug used to treat attention-deficit hyperactivity disorder (ADHD), may in rare instances cause prolonged [...]

Researchers have found that motivational incentives and methylphenidate may help improve cognitive control with children with attention-deficit hyperactivity disorder (ADHD). The authors used two electrophysiological indices of error monitoring which [...]

The authors of a case report report a 7-year-old male patient who presented with orofacial and limb dyskinesia after one dose of methylphenidate 18 mg for a diagnosis of attention-deficit [...]

Patient: Male, 15 years old Medication: methylphenidate osmotic release oral system (Concerta) Case: An adolescent boy was first seen at age 13 in an outpatient child and adolescent psychiatry clinic [...]

Methylphenidate (MPH) significantly improved apathy, depression, and functional status in a small group of patients with dementia of the Alzheimer type (DAT), in a 12-week, open-label study. Twenty-three community-dwelling patients [...]

Patient: Female, 8 years old Medications: Methylphenidate (Ritalin), diazepam (Valium), midazolem (Versed), phenobarbital Case: An 8-year-old girl, with DSM-IV attention-deficit/hyperactivity disorder (ADHD), combined subtype, was admitted to a pediatric emergency [...]

A 4-week, open-label study reports that beaded methylphenidate (BMPH), a long-acting formulation, was safe and effective in treating preschoolers with attention-deficit/hyperactivity disorder (ADHD). However, rates of adverse events (AEs) were [...], * 4-week, open-label study suggests long-acting MPH is safe and effective in treating preschoolers with ADHD. * Rates of adverse events were higher than previously reported in MPH trials of school-aged children. * 10-mg/day doses failed to achieve response in the 5 children who could not tolerate higher doses. * Future trials are needed with placebo controls and lower-dose formulations.

Addiction to internet video games may be a means of self-medication in patients with attention-deficit/hyperactivity disorder (ADHD). According to a new study, methylphenidate (MPH) may be a potential treatment for [...]

Mothers with attention-deficit/hyperactivity disorder (ADHD) and their children who have ADHD may both benefit from maternal treatment with osmoticrelease oral system (OROS) methylphenidate. A preliminary study found that maternal treatment [...]

Methylphenidate in an extended-release formulation (Concerta R) has been approved for treating attention-deficit/ hyperactivity disorder (ADHD) in adults. The new approval extends the drug's patient population from children and adolescents [...]

Patient: Female, 67 years old Medication: Methylphenidate (Ritalin) Case: A 67-year-old woman presented with complaints of restlessness and forgetfulness, which she had experienced since childhood. She had been working as [...]

precis * Results from a small, randomized, double-blind, placebo-controlled study of 26 nondemented adults (mean age 74 years) found that a single 20-mg dose of methylphenidate significantly improved measures of [...]

Patient: Male, 10 years old Medications: Methylphenidate OROS (Concerta), clonidine Case: A 10-year-old boy diagnosed with attention-deficit/hyperactivity disorder since age 6, and a history of in utero exposure to cocaine [...]